Table 4 Comparison of administration routes of WHO EMLc and drug products approved for children in China, the Russian Federation and Brazil

Oral

268 (55.3%)

158 (49.8%)

113 (50.4%)

122 (56.0%)

Injective

155 (32.0%)

119 (37.5%)

85 (37.9%)

74 (33.9%)

Topical

35 (7.2%)

23 (7.3%)

14 (6.3%)

13 (6.0%)

Nasal

9 (1.9%)

8 (2.5%)

4 (1.8%)

6 (2.8%)

Ophthalmic

11 (2.3%)

5 (1.6%)

3 (1.3%)

2 (0.9%)

Rectal

4 (0.8%)

2 (0.6%)

3 (1.3%)

1 (0.5%)

Otological

1 (0.2%)

1 (0.3%)

1 (0.4%)

–

Buccal

2 (0.4%)

1 (0.3%)

1 (0.4%)

–